Compared to non-targeted or monospecific liposomes, the advantage of bispecific FAP and endoglin targeting liposomes does not lie in increasing the overall level of cargo in the tumors per unit time per se, but in the precise delivery of the cargos into the distinct tumor stromal fibroblasts and tumor vascular endothelial cells simultaneously. The gene discussed is FAP; the disease is neoplasm.